Companies /Healthcare
Kymera Therapeutics Inc
NASDAQ: KYMR Biotechnology
$131.73
▲ $3.61 (+2.82%) today
Markets closed · 2:15am ET

Kymera Therapeutics (KYMR) Q3 2026 Earnings

Reported Oct 29, 2026, 7:10am ET · SEC source
$-1.32
Miss −4.22%
EPS · est. $-1.27 GAAP
$0
Miss +0.00%
Revenue · est. $2.9M
1 quarter
Consecutive EPS misses

How Did KYMR Stock React to Q3 2026 Earnings?

% change · around the report
−3%0+3%Oct 29Oct 30report 7:10am ETearnings−2.0%−0.0%
−3%0+3%Oct 29Oct 30earnings−2.0%−0.0%
KYMR −0.0%S&P 500 −2.0%
−3%0+3%Oct 29Oct 30report 7:10am ETearnings−4.1%−0.0%
−3%0+3%Oct 29Oct 30earnings−4.1%−0.0%
KYMR −0.0%NASDAQ −4.1%
0+7%+14%Oct 28Nov 5report 7:10am ETearnings−5.1%+5.4%
0+7%+14%Oct 28Nov 5earnings−5.1%+5.4%
KYMR +5.4%S&P 500 −5.1%
−8%0+8%+16%Oct 28Nov 5report 7:10am ETearnings−10.1%+5.4%
−8%0+8%+16%Oct 28Nov 5earnings−10.1%+5.4%
KYMR +5.4%NASDAQ −10.1%
+0.07%
Day of report
+3.29%
Next session
+4.50%
One week

Did KYMR Beat Earnings? Q3 2026 Results

No. Kymera Therapeutics reported Q3 2026 earnings of $-1.32 a share on Oct 29, 2026, missing the $-1.27 consensus estimate by 4.2%.

Kymera Therapeutics posted a disappointing third quarter 2026, missing on both the top and bottom lines while delivering clinical data that stole the spotlight from the financial results. The Cambridge-based company reported a GAAP net loss of $1.32 per share, coming in 4.22% below the consensus estimate of $1.27, as research and development expenses surged to $128.51 million from $74.09 million a year ago, driven by heavy investment in its STAT6 program and a larger R&D organization. Revenue was zero for the quarter, a full 100% decline from the prior-year period and well below the $2.95 million analysts had expected, as management does not anticipate recognizing any further collaboration revenue in 2026. The net loss widened to $132.00 million from $82.17 million. Investors had been closely watching for KT-579 Phase 1 data, and Kymera delivered, reporting at least 90% median IRF5 degradation and a clean safety profile. With $1.65 billion in cash providing runway into 2029, the company now looks toward year-end topline data from its KT-621 BROADEN2 atopic dermatitis trial as the next key catalyst.

Key Takeaways
  • R&D expenses rose to $128.5 million from $74.1 million on investment in the STAT6 program, platform and discovery programs, and R&D headcount growth
  • G&A expenses rose to $18.7 million from $17.3 million on higher legal and professional fees and personnel and facility costs
  • No collaboration revenue in Q3 2026, versus $2.8 million from Gilead in Q3 2025
  • Interest and other income increased to $15.3 million from $10.4 million

“The last patient has now completed their week 16 visit in our KT-621 BROADEN2 Phase 2b atopic dermatitis trial, and we plan to report topline data by year-end 2026. We also are planning to initiate our first Phase 3 AD trial by mid-2027, and report data from our BREADTH Phase 2b asthma trial in late 2027.”

Kymera Therapeutics CEO, on the earnings call

What Is Kymera Therapeutics's Outlook?

Kymera expects to report topline data from the KT-621 BROADEN2 Phase 2b atopic dermatitis trial by year-end 2026. Subject to regulatory discussions, it plans to initiate its first Phase 3 AD trial by mid-2027. Topline data from the KT-621 BREADTH Phase 2b asthma trial are expected in late 2027. The KT-579 LUMORA Phase 1b lupus trial is planned to start by early 2027. Gilead plans an IND filing for KT-200 in 2027. The company does not expect to recognize additional collaboration revenue in 2026. It expects its cash to fund operations into 2029, beyond multiple clinical inflection points.

KYMR YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$-400,000,000$-200,000,000$-360,244,678$-147,232,000Operating Income$-335,278,131$-131,999,000Net Income
$-400,000,000$-200,000,000Operating IncomeNet Income
KYMR income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Operating Income −$147.2M −$360.2M −59.1%
Net Income −$132.0M −$335.3M −60.6%

KYMR Revenue by Segment

Sanofi Collaboration
Gilead Sciences Collaboration

Figures from SEC filings and company reports. Not investment advice.